Flow cytometric analysis of aneuploidy and S-phase fraction in chronic myeloid leukemia patients: Role in early detection of accelerated phase

Leukemia Research

Volumn 27, Issue 10, 2003, Pages 899-902

  Tripathi, Anil K ^a,c   Chaturvedi, Rupesh ^a   Ahmad, Rizwan ^a   Asim, Mohd ^a   Sawlani, Kamal K ^a   Singh, Manoj K ^a   Tripathi, Payal ^a   Tekwani, Babu L ^b  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c NONE   (India)

Author keywords

Accelerated phase; Aneuploidy; CML; S phase fraction; SPF

Indexed keywords

ADOLESCENT; ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER PATIENT; CELL CYCLE S PHASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LEUKOCYTE; MALE; PARAMETER; PRIORITY JOURNAL;

EID: 0038691761     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00025-0     Document Type: Article

References (31)

1. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia [abstract]. Science. 132:1960;1497.
2. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., Baltimore D. The chronic myeloid leukemia-specific P210 protein is the product of the BCR/ABL hybrid gene. Science. 233:1986;212-214.
3. Cortes J.E., Talpaz M., Kantarjian H.M. Chronic myelogenous leukemia: a review. Am. J. Med. 100:1996;555-570.
4. Kantarjian H.M., Dixon D., Keating M.J.et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 61:1998;1441-1446.
5. Swolin B., Weinfeld A., Westin J., Waldenstrom J., Magnusson B. Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression. Cancer Genet Cytogenet. 18:1985;65-79.
6. O'Brien S.G. Autografting for chronic myeloid leukemia. Bailliere's Clin. Haematol. 10:1997;369-388.
7. Horowitz M.M., Rowlings P.A., Passweg J.R. Allogeneic bone marrow transplantation in CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 17(Suppl 3):1996;S5-S6.
8. Reiffers J., Goldman J., Meloni G., Cahn J.Y., Gratwohl A. Autologous stem cell transplantation in chronic myelogenous leukaemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant. 14:1994;407-410.
9. Kantarjian H.M., Keating M.J., Estey E.H.et al. Treatment of advanced stage of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon alfa and low dose of cytarabine. J. Clin. Oncol. 10:1992;772-778.
10. Cortes J., Talpaz M., O'Brien S.et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patient with Philadelphia chromosome-positive chronic myelogenous leukemia. J. Clin. Oncol. 16:1998;3279-3285.
11. Barlogie B., Alexanian R., Diixon D., Smith L., Smallwood L., Delasalle K. Prognostic implication of tumor cell DNA and RNA content in multiple myeloma. Blood. 66:1985;338-341.
12. Clark G.M., Mathieu M.C., Owens M.A.et al. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J. Clin. Oncol. 10:1992;428-432.
13. Christensson B., Tribukait B., Linder I.-L., Ullaman B., Biberfeld P. Cell proliferation and DNA content in non-Hodgkin's lymphoma flow cytometry in relation to lymphoma classification. Cancer-Philadelphia. 58:1986;1295-1304.
14. Hiddemann W., Wormann B., Ritter J.et al. Frequency and clinical significance of DNA aneuploidy in acute leukemia. Ann. New York Acad. Sci. 468:1986;227-240.
15. Shankey V.T., Kallioniemi O.P., Koslowski J.M.et al. Consensus review of clinical utility of DNA contents cytometry in prostate cancer. Cytometry. 14:1993;497-500.
16. Majlis A., Smith T.L., Talpaz M., O'Brien S., Rios M.B., Kantarjian H.M. significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J. Clin. Oncol. 14:1996;196-203.
17. Krishnan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 66:1975;188-193.
18. Duque E.R., Andreeff M., Braylan R.C., Diamond L.W., Peiper S.C. Consensus review of clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry. 14:1993;492-496.
19. Pinto A.E., Fonceca I., Soares J. The clinical relevance of ploidy and S-phase fraction determination in salivary gland tumors: a flow cytometric study of 97 cases. Cancer. 85:1999;273-281.
20. Yee K., Anglin P., keating A. Molecular approaches to the detection and monitoring of chronic myeloid leukemia: therapy and practice. Blood Rev. 13:1999;105-126.
21. Issaad C., Ahmed M., Novault S.et al. Biological effects induced by variable levels of BCR-ABL protein in pluripotent hematopoietic cell line UT-7. Leukemia. 14:2000;662-670.
22. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 BCR/ABL gene of the Philadelphia chromosome. Science. 247:1990;824-830.
23. Afar D.E., McLaughlin J., Sherr C.J., Witte O.N., Roussel M.F. Signaling by ABL oncogene through cyclin D. Proc. Natl. Acad. Sci. USA. 92:1995;9540-9544.
24. Pavithran K., Thomas M. Chronic myeloid leukemia - recent advances. J. Int. Med. India. 3:2000;91-97.
25. Rushing D., Goldman A., Gibbs G., Howe R., Kennedy B.J. Hydroxy-urea versus busulphan in the treatment of chronic myelogenous leukaemia. Am. J. Clin. Oncol. 5:1982;307-313.
26. Lengauer C., Kinzler K.W., Vogeistein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
27. Sen S. Aneuploidy and cancer. Curr. Opin. Oncol. 12:2000;82-88.
28. Ruff P., Saragas E., Poulos M., Weaving A. Patterns of clonal evolution in transformed chronic myelogenous leukaemia. Cancer Genet Cytogenet. 81:1995;182-184.
29. Sawyers C.L. Chronic myeloid leukemia. New Engl. J. Med. 340:1999;1330-1339.
30. Skorski T., Kanakaraj P., Nieborowaka-Skorska M.et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 86:1995;726-736.
31. McGahon A., Bissonnette R., Schmitt M., Cotter K.M., Green D.R., Cotter T.G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 83:1994;1179-1187.